Technologies related to NCI

Custom text
Immunogens for Use in a High Efficacy HIV Vaccine
Ref: NCI-E-160-2018 | Updated: 06/21/2021
Immunogens for Use in a High Efficacy HIV Vaccine
Ref: E-160-2018 | Updated: 06/21/2021
Polymer-Cast Inserts for Cell Histology and Microcopy
Ref: E-196-2018 | Updated: 06/21/2021
Polymer-Cast Inserts for Cell Histology and Microcopy
Ref: NCI-E-196-2018 | Updated: 06/21/2021
New Cancer Research Model: Spontaneously Transformed Mouse Epithelial Cancer Cell Lines
Ref: NCI-E-089-2010 | Updated: 06/04/2021
Software for Accurate Segmentation of Cell Nuclei in Breast Tissue
Ref: NCI-E-106-2010 | Updated: 06/04/2021
Tempol: A Commercially-Available Nitroxide as a Cancer Therapeutic
Ref: NCI-E-133-2009 | Updated: 06/04/2021
Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)
Ref: NCI-E-158-2010 | Updated: 06/04/2021
Biomarker for Predicting Taxane Chemotherapy Outcome
Ref: NCI-E-191-2009 | Updated: 06/04/2021
Polypeptides for Stimulation of Immune Response (Adjuvants)
Ref: NCI-E-185-2008 | Updated: 06/04/2021
Lentiviral Vectors with Dual Fluorescence/Luminescence Reporters
Ref: NCI-E-132-2011 | Updated: 06/04/2021
Phosphodiesterase as a target for cancer therapeutics
Ref: NCI-E-199-2010 | Updated: 06/04/2021
Diagnostic Marker for Improving Treatment Outcomes of Hepatitis C
Ref: NCI-E-217-2011 | Updated: 06/04/2021
Detection of Novel Endocrine-Disrupting Chemicals in Water Supplies
Ref: NCI-E-269-2011 | Updated: 06/04/2021
Diagnostic for Cancer of the Adrenal Glands and Adrenal Cortex
Ref: NCI-E-135-2012 | Updated: 06/04/2021
Cancer Therapies Using Engineered Monomeric Fc Molecules
Ref: NCI-E-019-2012 | Updated: 06/04/2021
Virus-Like Particles That Can Deliver Proteins and RNA
Ref: NCI-E-264-2011 | Updated: 06/04/2021
GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer
Ref: NCI-E-128-2009 | Updated: 06/04/2021
Mouse Xenograft Model for Mesothelioma
Ref: NCI-E-302-2009 | Updated: 06/04/2021
Human Monoclonal Antibodies Cross-reacting to Insulin-like Growth Factors IGF-I and IGF-II as Potential Anti-tumor Agents
Ref: NCI-E-068-2011 | Updated: 06/04/2021
Anti-Viral Compounds that Inhibit HIV Activity
Ref: NCI-E-081-2011 | Updated: 06/04/2021
Methods for Selection of Cancer Patients and Predicting Efficacy of Combination Therapy
Ref: NCI-E-013-2012 | Updated: 06/04/2021
Nitric Oxide-Releasing Polymers for Wound Healing
Ref: NCI-E-157-2012 | Updated: 06/04/2021
Nanoparticles for the targeted treatment of infected cells
Ref: NCI-E-039-2012 | Updated: 06/04/2021
Modified POTE Peptides for Cancer Immunotherapy
Ref: NCI-E-003-2010 | Updated: 06/04/2021
Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12
Ref: NCI-E-170-2009 | Updated: 06/04/2021
Software for Modeling Delivery and Penetration of Antibody Conjugates
Ref: NCI-E-060-2012 | Updated: 06/04/2021
BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research
Ref: NCI-E-009-2010 | Updated: 06/04/2021
Nitroxyl (HNO) Releasing Therapeutics
Ref: NCI-E-019-2010 | Updated: 06/04/2021
Dual-Function Protein ATIA for Diagnostics and Therapeutics of Glioblastoma
Ref: NCI-E-178-2009 | Updated: 06/04/2021
Treatment of Prostate Cancer Using Anti-androgen Small Molecules
Ref: NCI-E-015-2011 | Updated: 06/04/2021
Cancer Therapeutic based on Stimulation of Natural Killer T-cell Anti-tumor Activity
Ref: NCI-E-034-2010 | Updated: 06/04/2021
Improved Personalized Cancer Immunotherapy
Ref: NCI-E-059-2013 | Updated: 06/04/2021
Use of Cucurbitacins and Withanolides for the Treatment of Cancer
Ref: NCI-E-050-2010 | Updated: 06/04/2021
Immunocompetent Mouse Model for Tracking Cancer Progression
Ref: NCI-E-173-2010 | Updated: 06/04/2021
Topical Antibiotic for Faster Wound Healing
Ref: NCI-E-294-2011 | Updated: 06/04/2021
High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research
Ref: NCI-E-136-2012 | Updated: 06/04/2021
Human T Cell Receptors for Treating Cancer
Ref: NCI-E-269-2010 | Updated: 06/04/2021
Increased Therapeutic Effectiveness of PE-Based Immunotoxins
Ref: NCI-E-263-2011 | Updated: 06/04/2021
Nitric Oxide Based Therapeutics for the Treatment of Lung Cancer
Ref: NCI-E-025-2010 | Updated: 06/04/2021
Improved PE-based Targeted Toxins: A Therapeutic with Increased Effectiveness
Ref: NCI-E-269-2009 | Updated: 06/04/2021
MUC-1 Tumor Antigen Agonist Epitopes for Enhancing T-cell Responses to Human Tumors
Ref: NCI-E-001-2012 | Updated: 06/04/2021
Gene Signature for Predicting Solid Tumors Patient Prognosis
Ref: NCI-E-024-2009 | Updated: 06/04/2021
High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment
Ref: NCI-E-198-2012 | Updated: 06/04/2021
Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer
Ref: NCI-E-236-2012 | Updated: 06/04/2021
Co-Transcriptional Assembly of Modified RNA Nanoparticles
Ref: NCI-E-223-2012 | Updated: 06/04/2021
Video Monitoring and Analysis System for Vivarium Cage Racks
Ref: NCI-E-090-2013 | Updated: 06/04/2021
Her2 Monoclonal Antibodies, Antibody Drug Conjugates as Cancer Therapeutics
Ref: NCI-E-351-2013 | Updated: 06/04/2021
Non-invasive diagnostic and prognostic assay for early stage lung cancer
Ref: NCI-E-121-2013 | Updated: 06/04/2021
Assay to Screen Anti-metastatic Drugs
Ref: NCI-E-088-2013 | Updated: 06/04/2021
Mouse Model for the Preclinical Study of Metastatic Disease
Ref: NCI-E-296-2012 | Updated: 06/04/2021
Silica-Coated Nanodiamonds for Imaging and Delivery of Therapeutic Agents
Ref: NCI-E-175-2012 | Updated: 06/04/2021
Human Antibodies Against Middle East Respiratory Syndrome Coronavirus
Ref: NCI-E-002-2014 | Updated: 06/04/2021
Novel Anti-HIV Compounds Using Peptides or Peptide Mimetics
Ref: NCI-E-019-2014 | Updated: 06/04/2021
Natural product-based anti-cancer agents: aza-Englerin analogues
Ref: NCI-E-090-2014 | Updated: 06/04/2021
Nanoparticle delivery of lung cancer therapeutic
Ref: NCI-E-159-2014 | Updated: 06/04/2021
Modulating Chemotherapeutic Cytotoxicity
Ref: NCI-E-296-2011 | Updated: 06/04/2021
89Zr-Oxine Complex for In Vivo PET Imaging of Labelled Cells and Associated Methods
Ref: NCI-E-080-2014 | Updated: 06/04/2021
GTF2I Mutations as a Genetic Marker for Prognosis of Thymic Malignancies
Ref: NCI-E-109-2014 | Updated: 06/04/2021
Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen
Ref: NCI-E-021-2015 | Updated: 06/04/2021
Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations
Ref: NCI-E-028-2015 | Updated: 06/04/2021
Synthetic lipopeptide inhibitors of RAS oncoproteins
Ref: NCI-E-293-2010 | Updated: 06/04/2021
Novel Anti-HIV Proteins from Coral Reefs
Ref: NCI-E-295-2012 | Updated: 06/04/2021
T-Cell Therapy Against Patient-Specific Cancer Mutations
Ref: NCI-E-233-2014 | Updated: 06/04/2021
Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)
Ref: NCI-E-035-2013 | Updated: 06/04/2021
Nucleic Acid Nanoparticles for Triggering RNA Interference
Ref: NCI-E-156-2014 | Updated: 06/04/2021
Multifunctional RNA Nanoparticles as Cancer and HIV Therapeutics
Ref: NCI-E-765-2013 | Updated: 06/04/2021
Transgenic Mouse Model of Human Basal Triple Negative Breast Cancer
Ref: NCI-E-191-2010 | Updated: 06/04/2021
HIV-1 Therapeutic Inhibits Viral Entry
Ref: NCI-E-033-2013 | Updated: 06/04/2021
Zirconium-89 PET Imaging Agent for Cancer
Ref: NCI-E-111-2013 | Updated: 06/04/2021
Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents
Ref: NCI-E-167-2010 | Updated: 06/04/2021
Optical Microscope Software for Breast Cancer Diagnosis
Ref: NCI-E-286-2012 | Updated: 06/04/2021
Use of Anti-CD47 Antibodies for the Treatment of Cancer
Ref: NCI-E-263-2014 | Updated: 06/04/2021
High-throughput Assay to Identify New Cancer Drugs
Ref: NCI-E-031-2013 | Updated: 06/04/2021
3D Image Rendering Software for Biological Tissues
Ref: NCI-E-254-2012 | Updated: 06/04/2021
Novel Fusion Proteins for HIV Vaccine
Ref: NCI-E-256-2012 | Updated: 06/04/2021
Method for Generating Pluripotent and Multipotent Cells
Ref: NCI-E-086-2012 | Updated: 06/04/2021
Cancer Immunotherapy Using Virus-like Particles
Ref: NCI-E-050-2014 | Updated: 06/04/2021
Reporter Plasmid to Identify Cancer Stem Cells
Ref: NCI-E-141-2011 | Updated: 06/04/2021
Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers
Ref: NCI-E-001-2016 | Updated: 06/04/2021
Improved Production of Prenylated Protein in Insect Cells
Ref: NCI-E-009-2015 | Updated: 06/04/2021
Modified griffithsin tandemers for enhanced activity and reduced viral aggregation
Ref: NCI-E-034-2013 | Updated: 06/04/2021
Therapeutic antibody-drug conjugates targeting CD56-positive cancers
Ref: NCI-E-221-2015 | Updated: 06/04/2021
Biomarker signature development: microRNAs for biodosimetry
Ref: NCI-E-066-2015 | Updated: 06/04/2021
Metastatic ovarian cancer mouse models and cell lines for preclinical studies
Ref: NCI-E-069-2012 | Updated: 06/04/2021
Vaccines for HIV
Ref: NCI-E-087-2015 | Updated: 06/04/2021
Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma
Ref: NCI-E-211-2016 | Updated: 06/04/2021
B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia
Ref: NCI-E-163-2009 | Updated: 06/04/2021
Genomics-based Diagnostic Assay for Cancer
Ref: NCI-E-023-2009 | Updated: 06/04/2021
Ratio Based Biomarkers for the Prediction of Cancer Survival
Ref: NCI-E-025-2009 | Updated: 06/04/2021
Methods of analyzing virus-derived therapeutics
Ref: NCI-E-240-2015 | Updated: 06/04/2021
3D Image Rendering Software for Biological Tissues
Ref: E-254-2012 | Updated: 06/04/2021
Novel Fusion Proteins for HIV Vaccine
Ref: E-256-2012 | Updated: 06/04/2021
Method for Generating Pluripotent and Multipotent Cells
Ref: E-086-2012 | Updated: 06/04/2021
Cancer Immunotherapy Using Virus-like Particles
Ref: E-050-2014 | Updated: 06/04/2021
Reporter Plasmid to Identify Cancer Stem Cells
Ref: E-141-2011 | Updated: 06/04/2021
Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers
Ref: E-001-2016 | Updated: 06/04/2021
Improved Production of Prenylated Protein in Insect Cells
Ref: E-009-2015 | Updated: 06/04/2021
Modified griffithsin tandemers for enhanced activity and reduced viral aggregation
Ref: E-034-2013 | Updated: 06/04/2021
Therapeutic antibody-drug conjugates targeting CD56-positive cancers
Ref: E-221-2015 | Updated: 06/04/2021

Pages

Subscribe to Technologies related to NCI